Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease: Comment

Abstract

Dear Editor, We would like to share ideas on the publication “Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease” (1). Bronsky et al prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of their pediatric patients over 12 years old with IBD to that of healthy controls and looked for predictors of its robustness (1). Bronsky et al discovered that patients with IBD had higher levels of anti-spike S2 antibodies after vaccination than controls (1). Bronsky et al concluded that prior SARS-CoV-2 infection is associated with increased postvaccination antibody production and anti-tumor necrosis factor treatment with decreased production (1). To interpret the findings correctly, a number of elements need to be taken into account. One of the potential complicating factors that could have had an impact on the outcomes of the initial booster dose would be an exceptionally mild reaction. Without specialized laboratory testing, a link between asymptomatic COVID-19 and the absence of clinical symptoms may exist (2). A silent COVID-19 must be ruled out if neither the recent clinical symptoms nor the current clinical signs are present. It is impossible to totally rule out the possibility of cross-contamination with an undiagnosed SARS-Co-V2 infection. Depending on inherited genetic variability, various people’s immune systems appear to react to COVID-19 vaccines differently (3). More clinical research is required to add further evidence addressing the findings discussed in this paper and the clinical recommendations that derive from.